ReviewClinical interventions in aging2014
Selective estrogen receptor modulators: tissue specificity and clinical utility.
Review in Clinical interventions in aging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
122 citing papers in PubMed, 235 citations in OpenAlex.
- Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer.Cancer prevention research (Philadelphia, Pa.) · 2015Trial
- Low-dose tamoxifen ameliorates ovariectomy-induced metabolic and immune dysfunction.GeroScience · 2026Article
- Topical formulation of repurposed FDA-approved compounds inhibits Pseudomonas aeruginosa ExoU and improves corneal infection outcomes.PLoS pathogens · 2026Article
- Raloxifene relaxes the rat aorta via a mitochondria-dependent mechanism.Scientific reports · 2026Article
- 27-Hydroxycholesterol in bile duct tissue promotes cholangiocarcinoma progression through estrogen receptor signaling.American journal of cancer research · 2026Article
- Pharmacotherapeutic considerations of selective estrogen receptor modulators for vascular protection.Frontiers in pharmacology · 2026Review
- Estrogen signaling processes in fibroblasts: a scoping review.Frontiers in endocrinology · 2026Article
- Combined retinal vein occlusion and retinal artery occlusion in a patient undergoing therapy for metastatic breast cancer: a case report.Journal of medical case reports · 2025Article
- Clinical and genetic predictors of persistent chemotherapy-induced alopecia despite scalp cooling in breast cancer.NPJ breast cancer · 2025Article
- Improvement of Menopausal Symptoms byFood science & nutrition · 2025Article
- Estrogen Receptors as Key Factors in Carcinogenesis.Biomedicines · 2025Review
- Beyond Hot Flashes: The Role of Estrogen Receptors in Menopausal Mental Health and Cognitive Decline.Brain sciences · 2025Review
- Article
- Propolis mitigates histopathological alterations in the pituitary gland and reproductive system of female albino rats subjected to cadmium toxicity.Veterinary world · 2025Article
- PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.Targeted oncology · 2025Review
- CDK4/6 inhibitor-associated vortex keratopathy: a case report.BMC ophthalmology · 2025Article
- Transcriptional induction by ecdysone in Drosophila salivary glands involves an increase in chromatin accessibility and acetylation.Nucleic acids research · 2025Article
- Effects of tamoxifen on cognitive function in patients with primary breast cancer.British journal of cancer · 2025Article
- Molecular Docking and ADMET Analysis Strategy-based Stability Indicating RP-HPLC-PDA Method Development and Validation of Toremifene.Current computer-aided drug design · 2025Article
- Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action.Oncology reviews · 2025Review
62 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective estrogen receptor modulators (SERMs) are a diverse group of nonsteroidal compounds that function as agonists or antagonists for estrogen receptors (ERs) in a target gene-specific and tissue-specific fashion. SERM specificity involves tissue-specific expression of ER subtypes, differential expression of co-regulatory proteins in various tissues, and varying ER conformational changes induced by ligand binding. To date, the major clinical applications of SERMs are their use in the prevention and treatment of breast cancer, the prevention of osteoporosis, and the maintenance of beneficial serum lipid profiles in postmenopausal women. However, SERMs have also been found to promote adverse effects, including thromboembolic events and, in some cases, carcinogenesis, that have proven to be obstacles in their clinical utility. In this review, we discuss the mechanisms of SERM tissue specificity and highlight the therapeutic application of well-known and emergent SERMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.